Crewe Advisors LLC cut its holdings in shares of Solventum Co. (NYSE:SOLV – Free Report) by 56.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 382 shares of the company’s stock after selling 504 shares during the quarter. Crewe Advisors LLC’s holdings in Solventum were worth $27,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Copeland Capital Management LLC bought a new position in shares of Solventum in the third quarter worth $26,000. Mather Group LLC. purchased a new position in Solventum during the 3rd quarter valued at about $27,000. EverSource Wealth Advisors LLC bought a new stake in shares of Solventum during the first quarter valued at about $30,000. Hollencrest Capital Management bought a new stake in Solventum during the 2nd quarter worth approximately $25,000. Finally, Deseret Mutual Benefit Administrators purchased a new stake in Solventum in the 2nd quarter worth approximately $25,000.
Analyst Upgrades and Downgrades
SOLV has been the topic of several research analyst reports. Wells Fargo & Company decreased their price target on shares of Solventum from $69.00 to $64.00 and set an “equal weight” rating on the stock in a report on Friday, August 9th. Stifel Nicolaus initiated coverage on shares of Solventum in a research note on Tuesday, October 8th. They issued a “buy” rating and a $82.00 target price on the stock. Morgan Stanley lifted their target price on shares of Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a research report on Monday, November 11th. BTIG Research began coverage on shares of Solventum in a research report on Thursday, September 5th. They set a “neutral” rating on the stock. Finally, Wolfe Research assumed coverage on Solventum in a research note on Thursday, September 26th. They issued a “peer perform” rating for the company. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $68.00.
Solventum Price Performance
SOLV opened at $70.81 on Monday. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. Solventum Co. has a 52-week low of $47.16 and a 52-week high of $96.05. The stock’s 50 day moving average price is $70.53 and its 200-day moving average price is $62.30.
About Solventum
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.
Featured Stories
- Five stocks we like better than Solventum
- What is a SEC Filing?
- Disney’s Magic Strategy: Reinventing the House of Mouse
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Volatility in Semis? 3 Stable Alternatives to NVIDIA and SMCI
- How to Choose Top Rated Stocks
- Vertiv’s Cool Tech Makes Its Stock Red-Hot
Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Co. (NYSE:SOLV – Free Report).
Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.